Psychiatric and Cognitive Adverse Events of Eslicarbazepine Acetate (Esl) Monotherapy on Adults with Focal Seizures: Results from a Randomized, Double-Blind, Active-Controlled Study and a 2-Year Open-Label Extension Study
AuthID
P-00X-802
P-00X-802